Neurocrine Biosciences, Inc. (BMV:NBIX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 287.36B +21.3% |
| Revenue (ttm) | 58.95B +34.4% |
| Net Income | 12.33B +102.6% |
| EPS | 119.22 +101.2% |
| Shares Out | n/a |
| PE Ratio | 23.31 |
| Forward PE | 13.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93 |
| Open | 3,154.07 |
| Previous Close | 3,102.68 |
| Day's Range | 3,154.07 - 3,154.07 |
| 52-Week Range | 2,520.84 - 3,154.07 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial numbers in USD Financial StatementsNews
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocrine Bioscie...
Neurocrine Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenues exceeding $950 million, driven by strong performances from INGREZZA, CRENESSITY, and the newly acquired VYKAT XR. Guidance for INGREZZA was raised, and the company remains on track for key clinical milestones in 2027, supported by robust cash reserves and no debt.
Neurocrine Biosciences Earnings release: Q2 2026
Neurocrine Biosciences released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Neurocrine Biosciences Slides: Q2 2026
Neurocrine Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Neurocrine Biosciences Quarterly report: Q2 2026
Neurocrine Biosciences has published its Q2 2026 quarterly earnings report on July 30, 2026.
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Complet...
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the c...
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executiv...
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter...
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont i...
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing throug...
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among p...
Neurocrine Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company has evolved into a multi-product leader with strong revenue growth from INGREZZA, CRENESSITY, and VYKAT XR, supported by strategic acquisitions and a robust R&D pipeline. Key pipeline assets are set for major data readouts in 2027–2028, while ongoing investments in sales force and market education drive adoption and future growth.
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
New 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnor...
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within...
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care contin...
Neurocrine Biosciences Transcript: 46th Annual William Blair Growth Stock Conference
Significant transformation to a multi-product, high-growth company with strong cash flow and diversified revenue. Recent acquisition of Soleno Therapeutics expands the rare endocrine franchise, while robust R&D investment supports a broad pipeline and future growth.
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair 46 th Annu...
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social or physical impairment Following initiation of INGREZZA, 96% of patients with mild tardive dyskinesia...
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption...
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 M...
Neurocrine Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 performance was driven by INGREZZA, CRENESSITY, and the addition of VYKAT XR, with all products showing durable growth and long patent protection. The pipeline is robust, with key phase III readouts expected in 2027–2028, and the Soleno acquisition is immediately accretive.